Frontiers in Oncology (Sep 2020)

Pancreaticoduodenectomy for Retroperitoneal Sarcomas: A Mono-Institutional Experience in China

  • Cheng-Peng Li,
  • Zhen Wang,
  • Bo-Nan Liu,
  • Ang Lv,
  • Dao-Ning Liu,
  • Jian-Hui Wu,
  • Hui Qiu,
  • Chun-Yi Hao

DOI
https://doi.org/10.3389/fonc.2020.548789
Journal volume & issue
Vol. 10

Abstract

Read online

BackgroundEn bloc resection of retroperitoneal sarcoma (RPS) with adjacent organs such as pancreatic head and duodenum is challenging for surgeons. This mono-institutional study aims to evaluate the feasibility, safety, and outcome of performing pancreaticoduodenectomy (PD) during RPS resection.MethodsThe clinical data of RPS patients who underwent PD at the Sarcoma Center of Peking University Cancer Hospital from January 2011 to December 2019 was collected and analyzed.ResultsTwenty-seven patients out of a total of 264 surgically treated RPS underwent PD. The main pathological subtype was liposarcoma. All patients received concomitant resection of a median of three additional organs (range: 1–5), including 11 patients (40.7%) who underwent inferior vena cava resection and one patient who underwent segmental superior mesenteric-portal vein resection. Microscopic tumor infiltration to the duodenum or pancreas was observed in 81.5% of patients. Major complications occurred in 40.7% of patients; the reoperation rate was 22.2%. One patient (3.7%) died from liver abscess postoperatively. During a median follow-up of 18.9 months, 15 patients (55.6%) developed locally recurrent disease; two patients (7.4%) also had pulmonary metastases additionally. Twelve patients (44.4%) died from local relapse eventually.ConclusionPD during RPS resection is feasible, and it may be necessary to achieve complete resection. However, considering the complexity and risk, it should be performed by an experienced surgical team. The long-term survival benefit of this procedure should be verified by further large-scale multi-institutional studies.

Keywords